VCM
CDLX icon

Versant Capital Management’s Cardlytics CDLX Stock Holding History

Versant Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4
Closed -$396 – 1888
2023
Q4 		$396 Hold
4
– – ﹤0.01% 1732
2023
Q3 		$710 Hold
4
– – ﹤0.01% 1626
2023
Q2 		$272 Buy
+4
New +$242 ﹤0.01% 1949
2022
Q3 		– Sell
-1
Closed – – 1442
2022
Q2 		$0 Buy
+1
New +$335 ﹤0.01% 1459
2021
Q2 		– Hold
0
– – – 1455
2021
Q1 		– Hold
0
– – – 1522
2020
Q4 		– Hold
0
– – – 1352
2020
Q3 		– Hold
0
– – – 1314
2020
Q2 		– Hold
0
– – – 1313
2020
Q1 		– Hold
0
– – – 1339

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Versant Capital Management's CDLX Position: Q1 2024 in Review

Versant Capital Management sold out of Cardlytics (CDLX) in Q1 2024, closing a stake of 4 shares — an estimated $396 sold.

Versant Capital Management first reported a position in CDLX in Q2 2022 and held it in 4 quarters. The position peaked at $710 in Q3 2023. 144 funds tracked by Wall St. Rank hold CDLX as of Q1 2024.

  • Versant Capital Management reported no remaining Cardlytics position as of Q1 2024 after selling out during the quarter.
  • Versant Capital Management sold 4 Cardlytics shares in Q1 2024, an estimated $396.
  • Versant Capital Management first reported a position in Cardlytics in Q2 2022 and held it in 4 quarters.
  • Versant Capital Management's Cardlytics position peaked at $710 in Q3 2023.
  • 144 funds tracked by Wall St. Rank held Cardlytics as of Q1 2024.

Based on Versant Capital Management's 13F filing for Q1 2024, filed 3 Apr 2024.